

In the claims:

Please cancel claims 1-29, 32-60, 64-65, and 68 without prejudice.

Please add the following new claims:

71. (New) The method of claim 30, wherein the binding agent is selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment; a single chain antibody; a humanized antibody or fragment; a chimera antibody or fragment; a peptide; and a protein.

72. (New) The method of claim 30, wherein the binding agent is photoactivated.

73. (New) The method of claim 30, wherein the soluble antigen is associated with a human disease or condition.

74. (New) The method of claim 73, wherein the human disease or condition is selected from the group consisting of cancer; tumor; drugs of abuse; multiple sclerosis; allergy; human immunodeficiency virus; bacterial infection; autoimmune diseases; human viruses; and asthma.

75. (New) The method of claim 74, wherein the cancer is selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

76. (New) The method of claim 30, wherein the host is a human.

77. (New) The composition of claim 61, wherein the binding agent is selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment; a single chain antibody; a humanized antibody or fragment; a chimera antibody or fragment; a peptide; and a protein.

78. (New) The composition of claim 77, wherein the antibody is a monoclonal antibody.

79. (New) The composition of claim 78, wherein the monoclonal antibody is B43.13.

80. (New) The composition of claim 78, wherein the monoclonal antibody is AR20.5.

81. (New) The composition of claim 61, wherein the binding agent is photoactivated.

82. (New) The composition of claim 61, wherein the antigen is associated with a human disease or condition.

83. (New) The composition of claim 82, wherein the human disease or condition is selected from the group consisting of cancer; tumor; drugs of abuse; multiple sclerosis; allergy; human immunodeficiency virus; bacterial infection; autoimmune diseases; human viruses; and asthma.

no support
for
allergic
autoimmune
disease
MS
asthma

74, 83, 92

84. (New) The composition of claim 83, wherein the cancer is selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

85. (New) A composition for altering immunogenicity comprising an antigen and a binding agent that specifically binds to the antigen, wherein the binding agent and the antigen form a complex, and wherein administration of the composition to a host alters the host immune response against the antigen.

86. (New) The composition of claim 85, wherein the binding agent is selected from the group consisting of one member of an immunologic pair; an antibody; a monoclonal antibody; an antibody fragment; a single chain antibody; a humanized antibody or fragment; a chimera antibody or fragment; a peptide; and a protein.

87. (New) The composition of claim 85, wherein the antibody is a monoclonal antibody.

88. (New) The composition of claim 87, wherein the monoclonal antibody is B43.13.

89. (New) The composition of claim 87, wherein the monoclonal antibody is AR20.5.

90. (New) The composition of claim 85, wherein the binding agent is photoactivated.

91. (New) The composition of claim 85, wherein the antigen is associated with a human disease or condition.

92. (New) The composition of claim 91, wherein the human disease or condition is selected from the group consisting of cancer; tumor; drugs of abuse; multiple sclerosis; allergy; human immunodeficiency virus; bacterial infection; autoimmune diseases; human viruses; and asthma.

93. (New) The composition of claim 92, wherein the cancer is selected from the group consisting of breast, ovarian, prostate, and gastro-intestinal cancers.

94. (New) The composition of claim 85, wherein the antigen is a multi-epitopic antigen.

95. (New) The composition of claim 85, wherein the antigen is a soluble antigen.

96. (New) The composition of claim 85, wherein the host is a human.

97. (New) The composition of claim 85, wherein forming a complex between the binding agent and the antigen comprises exposing a previously inaccessible epitope on the antigen.